This can potentially impact drug metabolism and subsequent therapy response to commonly utilized therapeutics, such as doxorubicin, multi-kinase inhibitors (e.g., sorafenib), and other drugs ... In ...

Medications called CYP3A4 inhibitors block CYP3A4 from working ... Medications called CYP3A4 inducers stimulate the production of this enzyme. Higher levels of this enzyme can break down Ubrelvy ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary ...

evaluated via a hybrid bottom-up and top-down strategy the effect of DDI inducers or inhibitors of the CYP3A and CYP2C9 enzymes on ... to assess Siponimod DDI potential as substrate at a steady state ...

Angiogenesis is regulated by a complex set of inducers and inhibitors. In this paper we will present representative examples of both angiogenesis inducers and inhibitors that may regulate RA ...

Medicines called CYP3A4 inducers can decrease the blood levels ... Other medicines called P-gp, UGT1A1, and strong CYP3A inhibitors can also increase the amount of Sunlenca in the blood by a ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

The use of P-gp inducers is not recommended with ORLADEYO. ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index ...